Previous close | 85.59 |
Open | 85.71 |
Bid | 84.45 x 200 |
Ask | 84.61 x 100 |
Day's range | 84.07 - 86.45 |
52-week range | 73.68 - 99.56 |
Volume | |
Avg. volume | 2,479,761 |
Market cap | 16.062B |
Beta (5Y monthly) | 0.32 |
PE ratio (TTM) | 79.80 |
EPS (TTM) | 1.06 |
Earnings date | 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 108.23 |
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for BRINEURA® (cerliponase alfa) to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency. Previously, BRINEURA was indicated in symptomatic children 3 years of age and older with late infantile CLN2 d
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.